Non-opioid based target identified to potentially treat chronic pain
Researchers have discovered that blocking TRPC5 activity treated chronic pain in mouse models of various conditions.
List view / Grid view
Researchers have discovered that blocking TRPC5 activity treated chronic pain in mouse models of various conditions.
A wide range of tools to support your immuno-oncology research and help redefine and develop tailored, life-changing immunotherapies to fight cancer.
Chimeric antigen receptor (CAR) T and natural killer (NK) therapies may become the future of cancer treatment. Dr Jim Ross explains how bioelectronic assays are a non-invasive, label-free approach built for real-time, dynamic assessment of cell therapy potency.
Researchers have successfully created an unbiased, high-throughput microtitration assay for the quantification of Ebola virus in cell lines.
A synthetic antiviral named R327 has shown promise in initial tests against SARS-CoV-2 and is now advancing to the next stage of in vitro studies.
A new assay has been developed to screen for small molecule inhibitors of the Rh5 protein, which is essential for malaria parasite survival.
Researchers from the University of Minnesota have developed a 3D spherical microfluidic device. Here, Dr Ruitao Su explains how the new device can be used in drug discovery and development.
Microfluidic screening technologies have been used to discover a promising antibody candidate against SARS-CoV-2 and the South African variant.
A critical stage of the SARS-CoV-2 replication process, known as frameshifting, could be targeted by new drugs, researchers say.
Sino Biological has developed 1,000+ cytokines and receptors, including growth factors, cytokines, chemokines, interferons, interleukins, etc.
The global cell-based assays market is expected to grow due to increasing investments into cell-based research and a rise in chronic diseases.
Two screening techniques were used by researchers to find anticancer compounds that target the aryl hydrocarbon receptor.
Solutions to aid understanding of cellular and molecular pathways in diabetes and translate these findings into prevention and treatment strategies.
The development of a Parkinson’s disease model, using hiPSC-derived neural cells, to assess alpha-synuclein pre-formed fibril-induced toxicity.
11 May 2021 | By PerkinElmer
Get the Big Picture and listen to Pharma thought leaders how they view CETSA® and its impact on their Drug Discovery.